Validation of novel multiplex technologies
Journal Title: Advances in Precision Medicine - Year 2017, Vol 2, Issue 1
Abstract
Cytokine and chemokine levels in body fluid provide information of altered conditions in patients. The parallel analysis of multiple factors, such as cytokines, from small sample sizes is an interesting approach for the assessment of in vivo activation signatures and functionality after ex vivo stimulation. One interesting application is for therapy monitoring— such as safety data, pharmacodynamics, evidences for mode-of-action and side effects—which is particularly useful for accompanying early phase clinical trials. There are different platforms for multiplex analyses of ligands available. An assay validation of three different platforms for simultaneous quantification of cytokines (Luminex Bio-Plex® 200, Meso Scale Discovery® and Ella® ) was performed in this study. The comparison of multiplex platforms, which use different ways of achieving parallel measurements of biomarkers, reveal the performance strengths and weaknesses. We showed examples of in-house assessments of intra- and inter-assay variations, determination of the range and recovery of classical immunological serum markers and discussed advantages and disadvantages of these three platforms in relation to the question addressed. All the platforms show low intra-assay variances. The Luminex platform shows a high inter-assay variance for the majority of parameters, whereas the MSD and Ella platforms show low inter-assay variances.
Authors and Affiliations
Levent Akyüz, Andreas Wilhelm, Florian Butke, Park Su-Jin, Anja Kuckuck, Hans-Dieter Volk, Gerald Grütz
Keywords
Related Articles
- EP ID EP679265
- DOI -
- Views 178
- Downloads 0
Personalized medicine: consequences for drug research and therapy
In drug research, a serious transformation has taken place. With increasing knowledge gained from molecular medicine, it became possible to refine and develop new therapies based on the molecular mechanisms of diseases....
Strategy to achieve biomarker-driven immunosuppression after solid organ transplantation by an academic-industry partnership within the European BIO-DrIM consortium
Solid organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure as it improves both quality of life and survival. Despite the progress in short-term graft survival, that is closely asso...
Genomics Vault: A framework for precision medicine data management
A mixture of fumaric acid esters (FAEs) is approved for the oral therapy of psoriasis. However, for a long time the active ingredient of this mixture was unknown. We reviewed the in vitro data available for the different...
Reproducibility of preclinical data: one man's poison is another man's meat
Limited reproducibility of preclinical data is increasingly discussed in the literature. Failure of drug development programs due to lack of clinical efficacy is also of growing concern. The two phenomena may share an im...
Success factors in drug discovery and development
The article aimed to give a personal perspective on drug discovery and development. The author has worked both in Big Pharma as a scientist and manager and more recently also in start-up biotech companies. Drug companies...